PARP1 and prostate carcinoma: Small-molecule inhibition of Poly (ADP-ribose) polymerase 1 and 2 (PARP1/2) is an approved therapeutic strategy for the treatment of metastatic breast, ovarian, pancreatic and prostate cancers associated with Homologous Recombination (HR) defects, including mutations in BRCA1 gene.